# Efficacy and safety of valoctocogene roxaparvovec 4 years after gene transfer in GENEr8-1


Margareth C. Ozelo<sup>1</sup>, Andrew D. Leavitt<sup>2</sup>, Johnny Mahlangu<sup>3</sup>, Priyanka Raheja<sup>4</sup>, Emily Symington<sup>5</sup>, Doris V. Quon<sup>6</sup>, Adam Giermasz<sup>7</sup>, Gili Kenet<sup>8</sup>, Gillian Lowe<sup>5</sup>, Nigel S. Key<sup>9</sup>, Carolyn M. Millar<sup>10,11</sup>, Steven W. Pipe<sup>12</sup>, Bella Madan<sup>13</sup>, Sheng-Chieh Chou<sup>14</sup>, Robert Klamroth<sup>15,16</sup>, Jane Mason<sup>17,18</sup>, Hervé Chambost<sup>19</sup>, Flora Peyvandi<sup>20,21</sup>, Hua Yu<sup>22</sup>, Tara M. Robinson<sup>22</sup>

<sup>1</sup>Hemocentro UNICAMP, Department of Internal Medicine, School of Medical Sciences, University of California San Francisco, San Francisco, CA, USA; <sup>3</sup>Hemophilia Comprehensive Care Center, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand and NHLS, Johannesburg, South Africa; <sup>4</sup>The Royal London, UK; <sup>5</sup>West Midlands Adult Haemophilia Comprehensive Care Centre, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK; Orthopaedic Hemophilia Treatment Center, Los Angeles, CA, USA; The National Hemophilia Center and Amalia Biron Research Institute of Thrombosis and Hemostasis, Sheba Medical Center, Tel Hashomer, Tel Aviv University, Tel Aviv, Israel; <sup>9</sup>UNC Blood Research Center, University of North Carolina, Chapel Hill, NC, USA; <sup>10</sup>Centre for Haematology, Imperial College London, UK; <sup>11</sup>Imperial College Healthcare NHS Trust, London, UK; <sup>12</sup>Departments of Pediatrics and Pathology, University of Michigan, Ann Arbor, MI, USA; <sup>13</sup>Guy's and St Thomas' NHS Foundation Trust, London, UK; <sup>14</sup>Division of Hematology, Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; <sup>15</sup>Vascular Medicine and Haemostaseology, Vivantes Klinikum im Friedrichshain, Berlin, Germany; <sup>16</sup>Institute of Experimental Hematology and Transfusion Medicine, University of Bonn, Bonn, Germany; <sup>17</sup>Queensland Haemophilia Centre, Cancer Care Services, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia; <sup>18</sup>University of Queensland, Brisbane, QLD, Australia; <sup>19</sup>Department of Pediatric Hematology Oncology, Children Hospital La Timone & Aix Marseille University, INSERM, INRA, C2VN, Marseille, France; <sup>20</sup>Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; <sup>21</sup>Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy; <sup>22</sup>BioMarin Pharmaceutical Inc., Novato, CA, USA

### Introduction


### Valoctocogene roxaparvovec for severe hemophilia A

- Valoctocogene roxaparvovec (AAV5-hFVIII-SQ) is a liverdirected gene therapy that transfers a B-domain-deleted FVIII coding sequence to enable FVIII production in people with severe hemophilia A (FVIII  $\leq 1 \text{ IU/dL}$ )<sup>1,2</sup>
- In the open-label, phase 3 GENEr8-1 trial, participants who received 6x10<sup>13</sup> vg/kg valoctocogene roxaparvovec had improved protection from bleeds compared with regular FVIII prophylaxis over 3 years<sup>1,2</sup>
- Here, we evaluate efficacy and safety outcomes **4** years after treatment



### **FVIII** activity (mITT population)

### **FVIII** activity maintained between years 3 and 4



### Methods

### **Study design**

Because 2 participants did not reach year 4 follow-up, week 208 d ued the study, missing FVIII values post-discontinuation were impute


	Eligibility			Endpoints			
Adult men with severe hemophilia A (FVIII ≤1 IU/dL) Previously receiving FVIII prophylaxis No history of FVIII inhibitors or anti-AAV5 antibodies No significant liver dysfunction, fibrosis, or cirrhosis			Ch - / - /	<ul> <li>FVIII activity</li> <li>Change from baseline <ul> <li>Annualized bleeding rate</li> <li>Annualized FVIII infusion rate</li> <li>HRQOL (covered in a separate poster)</li> </ul> </li> <li>Safety</li> </ul>			
	Efficacy eva	luation period (start o	of week 5 or discontinua	ation of prophylaxis)			
Screening	Year 1	Year 2	Year 3	Year 4	Year 5 LTF		
· · · · · •	Rollover from BMN 270-9		<b>ITT population</b> articipants infused, N = 134	<b>Directly enrolled,</b> n = 22	2		
Participant dispos				Directly enrolled, n = 22			

HIV, human immunodeficiency virus; mITT, modified ITT; ITT, intention-to-treat



as 0 IU/dL through the data cutoff date. CSA, chromogenic substrate assay; mITT, modified intention-to-treat; Q, quartile; SE, standard error.

### FVIII activity ranges at the end of year 4





#### Most participants remain in the mild hemophilia range

Because 2 participants did not reach year 4 follow-up, week 208 data are based on 130 participants. For participants who discontinued the study, missing FVIII values post-discontinuation were imputed as 0 IU/dL through the data cutoff date. CSA, chromogenic substrate assay; FVIII, factor VIII; LLOQ, lower limit of quantification.

### Annualized bleed rate (Rollover population)

### **Reduction in treated bleeds maintained over 4 years**





#### In year 4, >70% of participants had no treated bleeds

Missing data were not imputed. ABR, annualized bleeding rate; CI, confidence interval; Q, quartile; SD, standard deviation.

### **Baseline characteristics**

Baseline characteristics	Rollover population N = 112	mITT N = 132	ITT N = 134
Age, years, mean (range)	31.8 (19–70)	31.4 (18–70)	31.7 (18–70)
Race, n (%)			
White	78 (69.6)	94 (71.2)	96 (71.6)
Asian	17 (15.2)	19 (14.4)	19 (14.2)
Black or African American	14 (12.5)	15 (11.4)	15 (11.2)
Hawaiian or Pacific Islander	1 (0.9)	1 (0.8)	1 (0.7)
Not provided	2 (1.8)	3 (2.3)	3 (2.2)
Hispanic or Latino ethnicity, n (%)	5 (4.5)	7 (5.3)	7 (5.2)
BMI, kg/m², mean ± SD	$25.2 \pm 4.7$	$25.3 \pm 4.6$	$25.3 \pm 4.6$
Medical history, n (%)			
Hepatitis B	17 (15.2)	18 (13.6)	20 (14.9)
Hepatitis C	33 (29.5)	39 (29.5)	41 (30.6)
HIV	0	0	2 (1.5)
Number of problem joints, <sup>a</sup> n (%)			
0	82 (73.2)	95 (72.0)	97 (72.4)
1	13 (11.6)	17 (12.9)	17 (12.7)
2	9 (8.0)	9 (6.8)	9 (6.7)
3	6 (5.4)	8 (6.1)	8 (6.0)
>3	2 (1.8)	3 (2.3)	3 (2.2)

<sup>a</sup>Problem joints were those with chronic joint pain, chronic synovitis, hemophilic arthropathy, limited motion, or recurrent bleeding. BMI, body mass index; HIV, human immunodeficiency virus; ITT, intention-to-treat; mITT, modified ITT; SD, standard deviation.


### Safety (ITT population)

### No new safety signals in year 4

- In year 4, no new safety signals were reported
- Low-grade, transient ALT elevations remained the most common AE in year 4
- No treatment-related SAEs occurred
- No new malignancies were reported
- As of the cutoff date, no FVIII inhibitors were observed and no thromboembolic events occurred

	Participants, n (%)	Year 1 (N = 134)	Year 2 (N = 134)	Year 3 (N = 131)	Year 4 (N = 131)	All follow-up
AEs		134 (100.0)	113 (84.3)	105 (80.2)	106 (80.9)	134 (100.0)
SAEs		21 (15.7)	6 (4.5)	9 (6.9)	13 (9.9)	37 (27.6)
Treatment-related AEs <sup>a</sup>		123 (91.8)	28 (20.9)	15 (11.5)	10 (7.6)	123 (91.8)
Glucocor	ticoid-related AEs <sup>a</sup>	80 (59.7)	10 (7.5)	1 (0.8)	1 (0.8)	81 (60.4)
AEs of	ALT elevation	114 (85.1)	40 (29.9)	31 (23.7)	56 (42.7)	121 (90.3)
	ALT elevation grade ≥3	11 (8.2)	1 (0.7)	0	1 (0.8) <sup>b</sup>	12 (9.0)
	Potential Hy's law case	0	0	0	0	0
	Infusion-related reactions <sup>c</sup>	12 (9.0)	0	0	0	12 (9.0)
special	Systemic hypersensitivity	7 (5.2)	0	0	0	7 (5.2)
interest	Anaphylactic or anaphylactoid reactions	3 (2.2)	0	0	0	3 (2.2)
	Thromboembolic events	0	0	0	0	0
	Anti-FVIII neutralizing antibodies	0	0	0	0	0
	Malignancy (except nonmelanoma skin cancer)	0	0	1 (0.8)	0	1 (0.7)


### Annualized FVIII infusion rate (Rollover population) Reduction of FVIII infusion rate maintained through year 4 Change in mean, -129.8 (95% CI, -139.4 to -120.1); P <0.0001



#### Annualized FVIII infusion rate decreased >95% from baseline during the post-prophylaxis period

Missing data were not imputed. AFR, annualized FVIII infusion rate; CI, confidence interval; Q, quartile; SD, standard deviation.

### **Return to prophylaxis (ITT population)** Most participants remain off prophylaxis



<sup>a</sup>Treatment-related and glucocorticoid-related AEs were assessed by the investigator. <sup>b</sup>This event was downgraded after the data cutoff (November 15, 2023). <sup>c</sup>Infusion-related reactions were defined as AEs occurring during valoctocogene roxaparvovec infusion or within 6 hours post-infusion. AE, adverse event; ALT, alanine aminotransferase; FVIII, factor VIII; SAE, serious AE.

### ALT elevation and glucocorticoid use

In year 4, 56 (42.7%) participants experienced an ALT elevation, most of which were low-grade and transient

No participants initiated glucocorticoids to manage ALT elevations after week 84

During year 4	With AEs in year 4 (N = 131)			
ALT elevation >ULN, n (%)	21 (16.0)			
ALT elevation >1.5x baseline, n (%)	55 (42.0)			
Used glucocorticoids for any purpose, n (%)	3 (2.3)			
Total duration, weeks, median (range)	1.4 (1.0–12.1)			
Total dose, mg, median (range)	200.0 (200–1475)			
Used glucocorticoids for ALT elevation, n (%)	0 (0.0)			
Total duration, weeks, median (range)	NA			
Total dose, mg, median (range)	NA			
AE, adverse event; ALT, alanine aminotransferase; NA, not applicable; ULN, upper limit of normal.				

Missing data were not imputed. ABR, annualized bleeding rate; CSA, chromogenic substrate assay; FVIII, factor VIII; RTP, return to prophylaxis

## Conclusions

A single infusion of valoctocogene roxaparvovec provides durable bleeding protection for 4 years with an acceptable safety profile

#### No new safety signals

- ALT elevation remained the most common AE in year 4; none have required glucocorticoid use since year 2
  - No FVIII inhibitors or thromboembolic events

#### **FVIII** activity was maintained

 FVIII activity remained in the mild hemophilia range Slope of decline in FVIII activity continues to approach 0

 Among the 17 participants dosed ≥5 years prior, year 5 values were similar to year 4

### References

#### **1.** Ozelo M, et al. *N Engl J Med.* 2022;386(11):1013-25. **2.** Mahlangu J, et al. *N Engl J Med.* 2023;388:694-705.

#### **Acknowledgements**

Thank you to all trial participants, their families, study-site personnel, and investigators. Funding for this study was provided by BioMarin Pharmaceutical Inc. Medical writing support was provided by Amin Ghane, PhD, of AlphaBioCom, a Red Nucleus company, and funded by BioMarin Pharmaceutical Inc. Project management support was provided by Gillian Clague, CMPP, of BioMarin Pharmaceutical Inc.



 $0 \wedge$ 

### ©2024 BioMarin Pharmaceutical Inc. All rights reserved.

**Durable hemostatic efficacy** 

post-prophylaxis period remains

decreased >80% from baseline

Decisions to return to prophylaxis

decision-making process that

considered multiple factors

were individual and part of a shared

Most participants had no treated

Most participants remain

bleeds during year 4

off prophylaxis

Rate of treated bleeds in the

Presented at HEMO 2024: October 23-26, 2024, São Paulo, Brazil